(51 days)
Not Found
No
The description focuses on the mechanical components and materials of the stent and delivery system, with no mention of AI or ML.
Yes
The device is indicated for "palliation of malignant neoplasms in the biliary tree," which describes a therapeutic action to relieve symptoms or improve quality of life for a medical condition.
No
The device is a stent system used for palliation of malignant neoplasms in the biliary tree, which is a treatment rather than a diagnostic function.
No
The device description clearly outlines physical components: an implantable stent made of Nitinol and a delivery system with a catheter. This is a hardware device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "palliation of malignant neoplasms in the biliary tree." This describes a therapeutic intervention performed within the patient's body to treat a condition.
- Device Description: The device is an implantable stent and a delivery system designed to be inserted into the biliary tree. This is a medical device used for treatment, not for testing samples outside the body.
- Lack of IVD Characteristics: There is no mention of analyzing samples (like blood, urine, tissue, etc.) or providing diagnostic information based on such analysis. The device's function is purely mechanical and therapeutic.
IVD devices are used to examine specimens derived from the human body to provide information for the diagnosis, monitoring, or treatment of a disease or condition. This device does not fit that description.
N/A
Intended Use / Indications for Use
The Epic Biliary Endoscopic Stent System is indicated for palliation of malignant neoplasms in the biliary tree.
Product codes
FGE
Device Description
The Epic Biliary Endoscopic Stent System is comprised of two components: the implantable stent and the stent delivery system. Epic Biliary Stent: The stent is a laser cut self-expanding stent composed of a nickel titanium alloy (Nitinol). The Epic Biliary Endoscopic Stent System is available in 6mm, 8mm, 10mm stent diameters and lengths of 40mm, 60mm, 80mm and 100 mm. On both the proximal and distal ends of the stent, radiopaque markers increase visibility of the stent to aid in placement. The stent is constrained within a 6 French delivery system. Delivery System: The delivery system is a coaxial design with an exterior shaft to protect and constrain the stent prior to deployment. The delivery system, with a 6 French outer diameter and 220 cm catheter length, is compatible with 0.035" (0.89 mm) guidewires. The stent is deployed by retracting the exterior shaft of the delivery system using either thumb wheel staged deployment method or the pull-back deployment method. A radiopaque marker at the distal end of the delivery system aids in visibility during deployment. The Epic Biliary Endoscopic Stent System is provided sterile and is a Single Use Device. The system is intended to track over a guidewire through an endoscope and into the area of a stricture.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
biliary tree
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Bench Testing: Functional and performance tests were performed on the proposed Epic Biliary Endoscopic stent and delivery system to demonstrate substantial equivalence and to satisfy all design verification requirements. The Epic Biliary Endoscopic Stent System passed all tests. In-vitro testing that has been performed and all components, subassemblies, and/or full devices met the required specifications. The proposed Epic Biliary Endoscopic Stent System and the Cook Zilver 635 Biliary Stent predicate were also tested to establish substantial equivalence in performance in the following tests: Flexural Rigidity, Stent Hoop Expansion Force, Stent Hoop Compression Force, System Deployment, Stent Dimensions, Delivery System Tensile Strength, and Stent Corrosion.
Biocompatibility Testing: The proposed Epic Biliary Endoscopic Stent System was evaluated in accordance with EN ISO 10993-1: 2009. The following tests were performed on the stent: Cytotoxicity, Sensitization, Intracutaneous Irritation, Systemic Toxicity, Subchronic Toxicity, Genotoxicity – Ames Assay and Mouse Lymphoma Assay, Implanatation, Chemical characterization. The following tests were performed on the delivery system: Cytotoxicity, Sensitization, Intracutaneous Irritation, Systemic Toxicity, Chemical Characterization Testing.
Conclusion: The information provided in this submission demonstrates that the proposed Epic Biliary Endoscopic Stent System is substantially equivalent to the Cook Zilver 635 Biliary Stent cleared in K163018.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5010 Biliary catheter and accessories.
(a)
Identification. A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.(b)
Classification. Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines representing hair or clothing.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
August 9, 2017
Boston Scientific Corporation Thomas Hirte Senior Manager Regulatory affairs 100 Boston Scientific Way Marlborough, MA 01752
Re: K171809
Trade/Device Name: Epic Biliary Endoscopic Stent System Regulation Number: 21 CFR§ 876.5010 Regulation Name: Biliary Catheter and Accessories Regulatory Class: II Product Code: FGE Dated: June 16, 2017 Received: June 19, 2017
Dear Thomas Hirte:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:
1
The safety and effectiveness of this device for use in the vascular system have not been established
Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
2
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
William H. Maisel -S
William H. Maisel, MD, MPH Acting Director, Office of Device Evaluation Deputy Center Director for Science Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
| | DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration | Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below. |
|--|-------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| | Indications for Use | |
| 510(k) Number (if known) | K171809 |
|---|---|
| Device Name | Epic Biliary Endoscopic Stent System |
| Indications for Use (Describe) | The Epic Biliary Endoscopic Stent System is indicated for palliation of malignant neoplasms in the biliary tree. |
| Type of Use (Select one or both, as applicable) | \u2612 Prescription Use (Part 21 CFR 801 Subpart D) \u25a1 Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
| FORM FDA 3881 (8/14) | Page 1 of 1 | PSC Publishing Services (301) 443-6740
EF |
| ---------------------- | ------------- | ---------------------------------------------- |
|---|
os i
4
510(K) SUMMARY SECTION 5.
510(k) SUMMARY
1. Submitter:
Boston Scientific Corporation 100 Boston Scientific Way Marlborough, MA 01752
Primary Contact: Thomas Hirte Senior Manager Regulatory Affairs Telephone: 508-683-4454 Fax: 508-683-5939
Secondary Contact: Virginia Garcia Principal, Regulatory Affairs Specialist Telephone: 508-683-4430 Fax: 508-683-5939
Date Prepared: 16 June 2017
2. Device:
| Trade Name: | Epic Biliary Endoscopic Stent System |
|---|---|
| Device Common Name: | Biliary Catheter and Accessories |
| Classification Name: | Catheter, Biliary, Diagnostic |
| Regulation Number: | 21CFR 876.5010 |
| Product Code: | FGE |
| Classification: | Class II |
-
- Predicate Device:
| Trade Name: | Cook Zilver 635 Biliary Stent |
|---|---|
| 510(k) Number: | K163018 |
| Device Common Name: | Biliary Catheter and Accessories |
| Classification Name: | Catheter, Biliary, Diagnostic |
| Regulation Number: | 21CFR 876.5010 |
| Product Code: | FGE |
| Classification: | Class II |
5
4. Device Description
The Epic Biliary Endoscopic Stent System is comprised of two components: the implantable stent and the stent delivery system. Epic Biliary Stent:
The stent is a laser cut self-expanding stent composed of a nickel titanium alloy (Nitinol). The Epic Biliary Endoscopic Stent System is available in 6mm, 8mm, 10mm stent diameters and lengths of 40mm, 60mm, 80mm and 100 mm. On both the proximal and distal ends of the stent, radiopaque markers increase visibility of the stent to aid in placement. The stent is constrained within a 6 French delivery system.
Delivery System:
The delivery system is a coaxial design with an exterior shaft to protect and constrain the stent prior to deployment. The delivery system, with a 6 French outer diameter and 220 cm catheter length, is compatible with 0.035" (0.89 mm) guidewires. The stent is deployed by retracting the exterior shaft of the delivery system using either thumb wheel staged deployment method or the pull-back deployment method. A radiopaque marker at the distal end of the delivery system aids in visibility during deployment.
The Epic Biliary Endoscopic Stent System is provided sterile and is a Single Use Device. The system is intended to track over a guidewire through an endoscope and into the area of a stricture. Table 5-1 below discusses the main features of the Epic Biliary Endoscopic Stent System.
5. Indications for Use:
The Epic Biliary Endoscopic Stent System is indicated for palliation of malignant neoplasms in the biliary tree.
Technological Characteristics 6.
The intended use of the proposed Epic Biliary Endoscopic Stent System is identical to the predicate Cook Zilver 635 Biliary Stent. They are both nitinol laser cut stents intended for use in palliation of malignant neoplasms in the biliary tree.
The proposed Epic Biliary Endoscopic Stent System is similar to the predicate Cook Zilver 635 Biliary Stent in terms of performance and technological characteristics with minor differences in the delivery system design. The stent design and materials are similar between the proposed Epic Biliary Endoscopic Stent and the Cook Zilver 635 Biliary Stent cleared in K163018.
6
7. Performance Data
Testing of the proposed device was performed in accordance with FDA Guidance Document "Guidance of the Content of Premarket Notifications for Metal Expandable Biliary Stents" February 5, 1998.
Bench Testing:
Functional and performance tests were performed on the proposed Epic Biliary Endoscopic stent and delivery system to demonstrate substantial equivalence and to satisfy all design verification requirements. The Epic Biliary Endoscopic Stent System passed all tests. In-vitro testing that has been performed and all components, subassemblies, and/or full devices met the required specifications.
The proposed Epic Biliary Endoscopic Stent System and the Cook Zilver 635 Biliary Stent predicate were also tested to establish substantial equivalence in performance in the following tests: Flexural Rigidity, Stent Hoop Expansion Force, Stent Hoop Compression Force, System Deployment, Stent Dimensions, Delivery System Tensile Strength, and Stent Corrosion.
The proposed Epic Biliary Endoscopic Stent System was evaluated in accordance with EN ISO 10993-1: 2009. The following tests were performed on the stent: Cytotoxicity, Sensitization, Intracutaneous Irritation, Systemic Toxicity, Subchronic Toxicity, Genotoxicity – Ames Assay and Mouse Lymphoma Assay, Implanatation, Chemical characterization. The following tests were performed on the delivery system: Cytotoxicity, Sensitization, Intracutaneous Irritation, Systemic Toxicity, Chemical Characterization Testing.
Conclusion
The information provided in this submission demonstrates that the proposed Epic Biliary Endoscopic Stent System is substantially equivalent to the Cook Zilver 635 Biliary Stent cleared in K163018.